Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial

Anne H Tavenier; Renicus S Hermanides; Jan Paul Ottervanger; Svetlana V Belitser; Olaf H Klungel; Arnoud W J van 't Hof; ON-TIME 3 investigators

doi:10.1016/j.ahj.2021.08.011

Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial

Am Heart J. 2022 Jan:243:39-42. doi: 10.1016/j.ahj.2021.08.011. Epub 2021 Sep 20.

Authors

Anne H Tavenier¹, Renicus S Hermanides², Jan Paul Ottervanger¹, Svetlana V Belitser³, Olaf H Klungel³, Arnoud W J van 't Hof⁴; ON-TIME 3 investigators

Affiliations

¹ Department of Cardiology, Isala, Zwolle, The Netherlands.
² Department of Cardiology, Isala, Zwolle, The Netherlands. Electronic address: r.s.hermanides@isala.nl.
³ Department of Pharmacoepidemiology, University of Utrecht, Utrecht, The Netherlands.
⁴ Department of Cardiology, Isala, Zwolle, The Netherlands; Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands; Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.

PMID: 34547260
DOI: 10.1016/j.ahj.2021.08.011

Abstract

Vomiting is associated with lower levels of ticagrelor concentration and higher platelet reactivity in the early hours of ST-elevation myocardial infarction. These results support reloading with a ticagrelor loading dose and/or treatment with intravenous platelet inhibitors when patients vomit.

Publication types

Letter

MeSH terms

Blood Platelets
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors
Platelet Function Tests
Purinergic P2Y Receptor Antagonists
ST Elevation Myocardial Infarction* / complications
ST Elevation Myocardial Infarction* / drug therapy
Ticagrelor / adverse effects
Treatment Outcome
Vomiting / chemically induced
Vomiting / drug therapy

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Ticagrelor